Market research
SWTX SpringWorks Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 47
- Dividend yield
- Not available
- Beta
- 0.7
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US85205L1070
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 47
- Dividend yield
- Not available
- Beta
- 0.7
About
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SWTX discussion.
5 years, 4 months ago
SpringWorks Therapeutics, Inc is currently in a long term uptrend where the price is trading 14.8% above its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 89.8.
SpringWorks Therapeutics, Inc's total revenue rose by inf% to $35M since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 189.9% to $14M since the same quarter in the previous year.
Based on the above factors, SpringWorks Therapeutics, Inc gets an overall score of 5/5.